Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ana Ojeda-Rodriguez

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Clinica E Investigacion En Arteriosclerosis : Publicacion Oficial De La Sociedad Espanola De Arteriosclerosis|December 3, 2025
Telomere length is associated with arterial damage in the CORDIOPREV studyAna Ojeda-Rodriguez, Maria Jose Parraga-Viudez, Alejandro López-Moreno, et al.
Clinica E Investigacion En Arteriosclerosis : Publicacion Oficial De La Sociedad Espanola De Arteriosclerosis|December 20, 2025
Risk of short telomere as biomarker of diabetes mellitus type 2 status in the CORDIOPREV studyAna Ojeda-Rodriguez, Maria Jose Parraga-Viudez, Juan L Romero-Cabrera, et al.
The American Journal of Clinical Nutrition|July 1, 2026
High postprandial endotoxemia is associated with recurrence of cardiovascular events in patients with coronary heart disease: from the CORDIOPREV randomized clinical trialJavier Arenas-Montes, Helena Garcia-Fernandez, Juan F Alcala-Diaz, et al.
Iscience|January 15, 2025
Differences in splicing factors may predict type 2 diabetes remission in the CORDIOPREV studyAna Ojeda-Rodriguez, Jose D Torres-Peña, Antonio Pablo Arenas-de Larriva, et al.
The Journal of Clinical Endocrinology and Metabolism|October 29, 2024
Decreased Neutrophils Are Associated With Reduced Risk of Type 2 Diabetes Incidence: Results From the CORDIOPREV StudyHatim Boughanem, Antonio Pablo Arenas de Larriva, Antonio Camargo, et al.
Nutrition & Diabetes|May 16, 2024
Mediterranean diet as a strategy for preserving kidney function in patients with coronary heart disease with type 2 diabetes and obesity: a secondary analysis of CORDIOPREV randomized controlled trialAlicia Podadera-Herreros, Antonio P Arenas-de Larriva, Francisco M Gutierrez-Mariscal, et al.
Antioxidants (Basel, Switzerland)|January 26, 2024
Telomere Maintenance Is Associated with Type 2 Diabetes Remission in Response to a Long-Term Dietary Intervention without Non-Weight Loss in Patients with Coronary Heart Disease: From the CORDIOPREV Randomized Controlled TrialAna Ojeda-Rodriguez, Juan F Alcala-Diaz, Oriol Alberto Rangel-Zuñiga, et al.
Atherosclerosis|August 7, 2023
Association between telomere length and intima-media thickness of both common carotid arteries in patients with coronary heart disease: From the CORDIOPREV randomized controlled trialAna Ojeda-Rodriguez, Juan F Alcala-Diaz, Oriol Alberto Rangel-Zuñiga, et al.
Cardiovascular Diabetology|March 17, 2024
Telomere length as biomarker of nutritional therapy for prevention of type 2 diabetes mellitus development in patients with coronary heart disease: CORDIOPREV randomised controlled trialAna Ojeda-Rodriguez, Oriol A Rangel-Zuñiga, Antonio P Arenas-de Larriva, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Clinica E Investigacion En Arteriosclerosis : Publicacion Oficial De La Sociedad Espanola De Arteriosclerosis|December 3, 2025
Telomere length is associated with arterial damage in the CORDIOPREV studyAna Ojeda-Rodriguez, Maria Jose Parraga-Viudez, Alejandro López-Moreno, et al.
Clinica E Investigacion En Arteriosclerosis : Publicacion Oficial De La Sociedad Espanola De Arteriosclerosis|December 20, 2025
Risk of short telomere as biomarker of diabetes mellitus type 2 status in the CORDIOPREV studyAna Ojeda-Rodriguez, Maria Jose Parraga-Viudez, Juan L Romero-Cabrera, et al.
The American Journal of Clinical Nutrition|July 1, 2026
High postprandial endotoxemia is associated with recurrence of cardiovascular events in patients with coronary heart disease: from the CORDIOPREV randomized clinical trialJavier Arenas-Montes, Helena Garcia-Fernandez, Juan F Alcala-Diaz, et al.
Iscience|January 15, 2025
Differences in splicing factors may predict type 2 diabetes remission in the CORDIOPREV studyAna Ojeda-Rodriguez, Jose D Torres-Peña, Antonio Pablo Arenas-de Larriva, et al.
The Journal of Clinical Endocrinology and Metabolism|October 29, 2024
Decreased Neutrophils Are Associated With Reduced Risk of Type 2 Diabetes Incidence: Results From the CORDIOPREV StudyHatim Boughanem, Antonio Pablo Arenas de Larriva, Antonio Camargo, et al.
Nutrition & Diabetes|May 16, 2024
Mediterranean diet as a strategy for preserving kidney function in patients with coronary heart disease with type 2 diabetes and obesity: a secondary analysis of CORDIOPREV randomized controlled trialAlicia Podadera-Herreros, Antonio P Arenas-de Larriva, Francisco M Gutierrez-Mariscal, et al.
Antioxidants (Basel, Switzerland)|January 26, 2024
Telomere Maintenance Is Associated with Type 2 Diabetes Remission in Response to a Long-Term Dietary Intervention without Non-Weight Loss in Patients with Coronary Heart Disease: From the CORDIOPREV Randomized Controlled TrialAna Ojeda-Rodriguez, Juan F Alcala-Diaz, Oriol Alberto Rangel-Zuñiga, et al.
Atherosclerosis|August 7, 2023
Association between telomere length and intima-media thickness of both common carotid arteries in patients with coronary heart disease: From the CORDIOPREV randomized controlled trialAna Ojeda-Rodriguez, Juan F Alcala-Diaz, Oriol Alberto Rangel-Zuñiga, et al.
Cardiovascular Diabetology|March 17, 2024
Telomere length as biomarker of nutritional therapy for prevention of type 2 diabetes mellitus development in patients with coronary heart disease: CORDIOPREV randomised controlled trialAna Ojeda-Rodriguez, Oriol A Rangel-Zuñiga, Antonio P Arenas-de Larriva, et al.
Pageof 1